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Summary
Background Treatment options are limited for patients infected by hepatitis C virus (HCV) with advanced liver disease. 
We assessed the safety and effi  cacy of ledipasvir, sofosbuvir, and ribavirin in patients with HCV genotype 1 or 4 and 
advanced liver disease.
Methods We did an open-label study at 34 sites in Europe, Canada, Australia, and New Zealand. Cohort A included 
patients with Child-Turcotte-Pugh class B (CTP-B) or CTP-C cirrhosis who had not undergone liver transplantation. 
Cohort B included post-transplantation patients who had either no cirrhosis; CTP-A, CTP-B, or CTP-C cirrhosis; or 
fi brosing cholestatic hepatitis. Patients in each group were randomly assigned (1:1) using a computer-generated 
randomisation sequence to receive 12 or 24 weeks of ledipasvir (90 mg) and sofosbuvir (400 mg) once daily (combination 
tablet), plus ribavirin (600–1200 mg daily). The primary endpoint was the proportion of patients achieving a sustained 
virological response 12 weeks after treatment (SVR12). All patients who received at least one dose of study drug were 
included in the safety analysis and all patients who received at least one dose of study drug and did not undergo liver 
transplantation during treatment were included in the effi  cacy analyses. Estimates of SVR12 and relapse rates and their 
two-sided 90% CI (Clopper-Pearson method) were provided. This exploratory phase 2 study was not powered for formal 
comparisons among treatment groups; no statistical hypothesis testing was planned or conducted. The trial is registered 
with EudraCT (number 2013-002802-30) and ClinicalTrials.gov (number NCT02010255).
Findings Between Jan 14, 2014, and Aug 19, 2014, 398 patients were screened. Of 333 patients who received treatment, 
296 had genotype 1 HCV and 37 had genotype 4 HCV. In cohort A, among patients with genotype 1 HCV, SVR12 was 
achieved by 20 (87%, 90% CI 70–96) of 23 CTP-B patients with 12 weeks of treatment; 22 (96%, 81–100) of 23 CTP-B 
patients with 24 weeks of treatment; 17 (85%, 66–96) of 20 CTP-C patients (12 weeks treatment); and 18 (78%, 60–91) 
of 23 CTP-C patients (24 weeks treatment). In cohort B, among patients with genotype 1 HCV, SVR12 was achieved 
by 42 (93%, 84–98) of 45 patients without cirrhosis (12 weeks treatment); 44 (100%, 93–100) of 44 patients without 
cirrhosis (24 weeks treatment); 30 (100%, 91–100) of 30 CTP-A patients (12 weeks treatment); 27 (96%, 84–100) of 
28 CTP-A patients (24 weeks treatment); 19 (95%, 78–100) of 20 CTP-B patients (12 weeks treatment); 20 (100%, 
86–100) of 20 CTP-B patients (24 weeks treatment); one (50%, 3–98) of two CTP-C patients (12 weeks treatment); and 
four (80%, 34–99) of fi ve CTP-C patients (24 weeks treatment). All fi ve patients with fi brosing cholestatic hepatitis 
achieved SVR12 (100%, 90% CI 55–100). Among all patients with genotype 4 HCV, SVR12 was achieved by 14 (78%, 
56–92) of 18 patients (12 weeks treatment) and 16 (94%, 75–100) of 17 patients (24 weeks treatment). Seven patients 
(2%) discontinued ledipasvir–sofosbuvir prematurely due to adverse events. 17 patients died, mainly from 
complications of hepatic decompensation.
Interpretation Ledipasvir–sofosbuvir and ribavirin provided high rates of SVR12 for patients with advanced liver 
disease, including those with decompensated cirrhosis before or after liver transplantation.
Funding Gilead Sciences. 
Introduction
Patients with chronic hepatitis C virus (HCV) infection 
with advanced fi brosis or cirrhosis are at increased risk of 
hepatocellular carcinoma, liver failure, liver trans plantation, 
and both liver-related and all-cause mortality.1 For patients 
who undergo liver transplantation with detectable HCV, 
recurrent infection is universal. In some transplantation 
patients, recurrent HCV infection leads to an aggressive 
course of disease known as fi brosing cholestatic hepatitis, 
which is characterised by increased risk of cirrhosis, hepatic 
decompensation, and death.2 Despite the serious risks for 
patients with HCV with advanced liver disease, treatment 
options for these patients are limited.
The nucleotide analogue sofosbuvir is a direct-acting 
inhibitor of the HCV NS5B polymerase and was approved 
in the USA in 2013 and in Europe in early 2014.3,4 In 
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phase 2 trials, sofosbuvir plus ribavirin was eff ective in 
treating patients before and after liver transplantation, 
including those with compensated cirrhosis.5–7 The 
combination of sofosbuvir and ribavirin was given for 
24–48 weeks, which might be cumbersome for patients 
with advanced disease who could have diffi  culty tolerating 
the haematological side-eff ects associated with ribavirin.
In 2014, a fi xed-dose combination of sofosbuvir with the 
HCV NS5A inhibitor ledipasvir was approved in the USA 
for treating chronic genotype 1 HCV infection and in 
Europe for treating genotypes 1 or 4 infection.8,9 In a 
phase 2 study of HCV genotype 1 patients with 
compensated cirrhosis, the combination of sofosbuvir and 
ledipasvir for 24 weeks led to a sustained virological 
response (SVR) rate of 97%.10 In the US-based SOLAR-1 
study,11 the combination of sofosbuvir, ledipasvir, and 
ribavirin for 12 or 24 weeks had moderate-to-high SVR 
rates in HCV patients, predominantly with HCV genotype 
1a, who had advanced liver disease, including those who 
had undergone liver transplantation. Here we present the 
results of the international SOLAR-2 study, in which we 
similarly assessed the safety and effi  cacy of sofosbuvir, 
ledipasvir, and ribavirin for 12 or 24 weeks in HCV 
genotype 1a, 1b, or 4 patients with advanced liver disease, 
including post-transplantation patients with fi brosing 
cholestatic hepatitis. This phase 2 study was exploratory 
and not powered to permit comparisons among groups; 
no statistical hypothesis testing was planned or conducted.
Methods
Study design and participants
We did an open-label, phase 2 study at 34 clinical sites in 
Europe, Canada, Australia, and New Zealand (six in 
Canada, four in France, four in Germany, four in Spain, 
three in the UK, two in Australia, two in Austria, two in 
Belgium, two in Italy, two in the Netherlands, two in 
Switzerland, and one in New Zealand). Eligible patients 
were at least 18 years old and chronically infected with 
genotype 1 or 4 HCV.
Patients were enrolled in two cohorts. In both cohorts, 
the presence of cirrhosis was established by either liver 
biopsy, FibroScan scores greater than 12·5 kPa, or 
FibroTest scores greater than 0·75, and an aspartate 
aminotransferase to platelet ratio of more than 2. 
Cohort A consisted of patients who had not undergone 
liver transplantation and had decompensated cirrhosis 
with either moderate hepatic impairment (Child-
Turcotte-Pugh class B [CTP-B]; group 1) or severe hepatic 
impairment (CTP-C; group 2). Cohort B consisted of fi ve 
groups of patients who had previously undergone liver 
transplantation: group 3 patients did not have cirrhosis, 
group 4 patients had compensated cirrhosis and mild 
hepatic impairment (CTP-A), group 5 patients had 
decompensated cirrhosis and moderate hepatic impair-
ment (CTP-B), group 6 patients had decom pensated 
cirrhosis and severe hepatic impairment (CTP-C), and 
group 7 patients had fi brosing cholestatic hepatitis. In 
both cohorts, enrolment of patients with CTP-C class 
hepatic impairment was restricted to patients with scores 
of 10–12 points (appendix).
Patients in cohort B, groups 3–6 had to have undergone 
liver transplantation at least 3 months before initiation of 
study treatment. Patients in cohort B, group 7 had to have 
undergone liver transplantation at least 2 months, but 
not more than 18 months, before initiation of study 
treatment and have histological evidence of fi brosing 
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Evidence before this study
This study was designed in the fi rst half of 2013, before any all-
oral regimens for hepatitis C virus (HCV) had been approved. 
We did PubMed searches for articles using the search terms 
“HCV treatment”, “decompensated cirrhosis”, and “post-liver 
transplant” from inception until Feb 20, 2013. There were no 
language restrictions for this search. We found no reports on 
the use of direct-acting antivirals in all-oral regimens for HCV in 
patients with advanced fi brosis or decompensated cirrhosis.
Added value of this study
This study assessed the safety and effi  cacy of the all-oral regimen 
of ledipasvir, sofosbuvir, and ribavirin in patients with HCV who 
have advanced liver disease or have had a liver transplant. The 
results show that ledipasvir–sofosbuvir plus ribavirin for 12 weeks 
is an eff ective treatment for patients with advanced liver disease, 
including those with decompensated liver function before and 
after liver transplantation. These patients, who are at substantial 
risk for mortality, had no eff ective treatment options until 
recently. Extending treatment to 24 weeks did not appear to be 
associated with improved outcomes.
Implications of all the available evidence
Similar results were recorded in the SOLAR-1 study, which also 
assessed ledipasvir, sofosbuvir, and ribavirin treatment in 
patients with advanced liver disease before and after liver 
transplantation, but which enrolled almost exclusively patients 
with genotype 1 HCV (99%). The recent CORAL-1 study 
showed that 97% of patients with mild histological recurrent 
HCV after liver transplantation achieved sustained virological 
response after treatment with the combination of 
ombitasvir–paritaprevir–ritonavir and dasabuvir plus ribavirin 
for 24 weeks. The three studies meet a crucial need of assessing 
novel therapies in patients who have limited treatment 
options. Our fi ndings support the effi  cacy and safety of 
ledipasvir–sofosbuvir plus ribavirin in patients with 
decompensated liver disease before and after liver 
transplantation, and suggest that there is no clinically 
signifi cant interaction between ledipasvir–sofosbuvir and 
common immunosuppressive agents used in liver transplant 
recipients. 
See Online for appendix
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cholestatic hepatitis in the previous 6 months, bilirubin 
at least 2·5 times the upper limit of normal, and no 
evidence of hepatic artery thrombosis in the previous 
6 months. Also for this group, any patients with 
alternative explanations for their cholestasis or 
hyperbilirubinaemia, such as biliary or hepatic artery 
complications or drug-induced injury, would not be 
eligible.
Patients co-infected with HIV or hepatitis B virus or 
those with previous exposure to an NS5A inhibitor were 
excluded. Patients could not have had treatment with 
interferon, ribavirin, telaprevir, boceprevir, or any other 
HCV drugs within 1 month before screening. Additional 
details on exclusion criteria can be found in the appendix.
The design of this study, which was in compliance with 
the principles of the Declaration of Helsinki, Good 
Clinical Practice guidelines, and local regulatory require-
ments, was approved by the institutional review board or 
independent ethics committee at each participating site. 
The study was done according to the protocol of the 
funder (Gilead Sciences) in collaboration with the 
academic investigators.
Randomisation
Patients in each of the seven groups were randomly 
assigned using a computer-generated randomisation 
sequence generated by Bracket (San Francisco, CA, USA) 
and allocated by means of an interactive web response 
system (1:1 ratio) to receive either 12 or 24 weeks of 
treatment with ledipasvir 90 mg and sofosbuvir 400 mg 
in a fi xed-dose combination tablet (ledipasvir–sofosbuvir) 
once daily plus ribavirin.
Procedures
For groups 1, 2, 5, and 6, ribavirin was given at a starting 
dose of 600 mg per day divided morning and evening. If 
the starting dose was well tolerated and haemoglobin 
concentrations remained above 10 g/dL without 
haematological growth factor support, the dose could be 
increased to 1000 mg daily in patients weighing less than 
75 kg and 1200 mg daily in patients weighing at least 
75 kg. For patients who could not tolerate the starting 
dose of 600 mg, the dose was reduced as necessary. For 
groups 3, 4, and 7, ribavirin was given orally twice daily 
via weight-based dosing (1000 mg per day for patients 
weighing less than 75 kg and 1200 mg per day for patients 
weighing at least 75 kg).
Management of immunosuppression was not specifi ed 
in the clinical protocol, but treatments and dose 
adjustments were recorded to assess any possible eff ect 
on the resolution of HCV infection. Patients who under-
went liver transplantation during the study discontinued 
all study drugs about 24 h before transplantation.
Serum HCV RNA was measured using the COBAS 
AmpliPrep/COBAS Taqman HCV Test, version 2.0, for 
use with the High Pure System (Roche Molecular 
Diagnostics, Pleasanton, CA, USA). HCV genotype and 
subtype were identifi ed using the VERSANT HCV 
Genotype INNO-LiPA 2.0 assay, the TRUGENE HCV 
5ʹNC Geno typing Assay (Siemens, Munich, Germany), 
and NS5B sequencing. IL-28B genotype was determined 
by PCR amplifi cation of the single-nucleotide 
polymorphism rs12979860.
For analysis of viral resistance, samples were collected 
at baseline from all patients. The HCV NS5A and NS5B 
coding regions were amplifi ed using standard RT-PCR. 
Ultradeep sequencing was done. Variants present at 
more than 1% of sequence reads were reported. For 
patients who had virological failure, sequencing was 
again done for the HCV NS5A and NS5B coding regions, 
with samples collected at the fi rst virological failure 
timepoint. Variants in NS5A and NS5B coding regions 
present in at least 1% of the viral population were 
compared with the respective baseline sequence.
Outcomes
The primary effi  cacy endpoint was the proportion of 
patients achieving an SVR 12 weeks after the end of 
therapy (SVR12), defi ned as serum HCV RNA below the 
lower limit of quantifi cation (LLOQ, 15 IU/mL). 
Secondary endpoints included improvements in CTP 
and Model for End-stage Liver Disease (MELD) scores at 
12 weeks after treatment for all patients who achieved 
SVR12. The primary safety endpoint was the proportion 
of patients who discontinued study treatment because of 
an adverse event.
Statistical analysis
All patients who received at least one dose of study drugs, 
met criteria for one of the seven disease groups, and did 
not have an on-study transplant while on treatment or 
within 70 days post-treatment with HCV RNA below the 
LLOQ at last measurement before transplantation were 
included in the primary effi  cacy analysis. For each group 
and treatment duration, the percentages of patients with 
SVR12 were calculated along with a two-sided 90% CI 
(using the Clopper-Pearson method). We randomised the 
assignment of patients to 12 or 24 weeks of treatment 
within each of the seven disease groups to ensure that an 
equal number of patients received both durations of 
treatment within each disease group and that patient 
assignment within disease group was random. No 
hypothesis testing of the primary effi  cacy outcome was 
planned or done.
Except for group 3, all groups had an enrolment target 
of 50 patients. The enrolment target for group 3 (post-
transplantation without cirrhosis) was 100 patients. The 
enrolment targets were not based on a formal sample 
size calculation but were believed to provide a reasonable 
estimate of SVR12 with appropriate 90% CIs. No formal 
comparisons between groups or between treatment 
durations within each group were planned.
Patients who underwent liver transplantation from 
day 1 to day 70 after treatment (the beginning of the 
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post-treatment week 12 visit window) with HCV RNA 
less than 15 IU/mL at last measurement before 
transplantation were excluded from the numerator and 
denominator for the primary effi  cacy analysis (SVR12). 
Instead, effi  cacy in these patients was assessed in a 
separate analysis. For all patients who received a 
transplant on study with HCV RNA less than 15 IU/mL 
at their last measurement before transplantation, the rate 
of post-transplantation virological response (pTVR12, 
defi ned as HCV RNA <15 IU/mL 12 weeks after date of 
transplantation) was calculated.
Role of the funding source
The funder collected the data, monitored the conduct of 
the study, and did the statistical analyses. An independent 
data and safety monitoring committee reviewed the 
progress of the study. The investigators, participating 
institutions, and funder agreed to maintain confi dentiality 
of the data. All authors had access to the data and assume 
responsibility for the integrity and completeness of the 
data and analyses reported. The fi rst draft of the 
manuscript was prepared by a professional writer paid by 
Gilead Sciences and the corresponding author, with 
input from all the authors.
Results
Between Jan 14, 2014, and Aug 19, 2014, 398 patients were 
screened, of which 333 received at least one dose of study 
treatment (fi gure 1, appendix). Of these 333 patients, 
296 (89%) patients had genotype 1 HCV infection (n=163 
genotype 1a and n=133 genotype 1b), and 37 (11%) had 
genotype 4 HCV infection (table 1). Among 227 patients 
enrolled with cirrhosis, 67 had CTP-A liver disease, 
101 had CTP-B liver disease, and 59 had CTP-C liver 
disease. Of the 226 patients who had undergone liver 
transplantation before enrolment, 101 had Metavir F0–F3 
fi brosis, 67 had CTP-A liver disease, 45 had CTP-B liver 
disease, eight had CTP-C liver disease, and fi ve had 
fi brosing cholestatic hepatitis. In each of the treatment 
groups, patients were predominantly white and male, 
and most had previously received treatment for HCV.
Among patients with genotype 1 HCV and CTP-B 
disease who had not undergone transplantation, SVR12 
was achieved by 20 (87%, 90% CI 70–96) of 23 patients 
receiving 12 weeks of treatment and 22 (96%, 81–100) of 
23 patients receiving 24 weeks of treatment (table 2). For 
patients with genotype 1 HCV and CTP-C disease, SVR12 
was achieved by 17 (85%, 66–96) of 20 patients receiving 
12 weeks of treatment and by 18 (78%, 60–91) of 
23 patients receiving 24 weeks of treatment. In total, 
12 patients did not achieve SVR12: six had virological 
relapse (four in the 12-week group and two in the 24-week 
group), fi ve died (two in the 12-week group and three in 
the 24-week group), and one patient in the 24-week group 
withdrew consent. Six patients underwent liver 
transplantation before SVR12 with HCV RNA less than 
the LLOQ at transplantation (four in the 12-week group, 
two in the 24-week group). All six of these patients still 
had HCV RNA less than LLOQ 12 weeks post-
transplantation.
Among HCV genotype 1 liver transplant recipients 
without cirrhosis, SVR12 was achieved by 42 (93%, 
84–98) of 45 patients receiving 12 weeks of treatment and 
44 (100%, 93–100) of 44 patients receiving 24 weeks of 
treatment. In liver transplant recipients with CTP-A 
disease, SVR12 was achieved by 30 (100%, 91–100) of 
30 patients receiving 12 weeks of treatment and 27 (96%, 
84–100) of 28 patients receiving 24 weeks of treatment. In 
total, four patients did not achieve SVR12: one non-
cirrhotic patient receiving 12 weeks of treatment had a 
relapse, and three died (two non-cirrhotic patients 
receiving 12 weeks of treatment and one with CTP-A 
cirrhosis receiving 24 weeks of treatment). None of the 
deaths were considered related to study drug.
In liver transplant recipients with genotype 1 HCV and 
CTP-B cirrhosis, SVR12 was achieved by 19 (95%, 78–100) 
of 20 patients receiving 12 weeks of treatment and 20 
(100%, 86–100) of 20 patients receiving 24 weeks of 
treatment (table 2). Of the two patients with CTP-C 
cirrhosis who received 12 weeks of treatment, one 
achieved SVR12. Of the fi ve patients with CTP-C cirrhosis 
who received 24 weeks of treatment, four achieved 
SVR12. Three transplant recipients with CTP-B or CTP-C 
cirrhosis did not achieve SVR12 because they died.
All fi ve patients with fi brosing cholestatic hepatitis—
three receiving 12 weeks of treatment and two receiving 
24 weeks of treatment—achieved SVR12.
Estimates (95% CI) of SVR12 and relapse rates for the 
12-week and 24-week groups and the diff erence (95% CI 
on diff erence) between groups did not show any 
statistically signifi cant diff erences (95% CI on diff erence 
included 0) between the 12-week and 24-week groups for 
SVR12 or virological relapse (data not shown). However, 
the groups were not powered for such comparisons so 
this analysis does not show equivalent effi  cacy of the 
12-week and 24-week treatment durations.
For analysis of relapse rates, patients who were 
transplanted before post-treatment week 12 with last 
HCV RNA less than LLOQ before transplantation and 
patients with other virological outcomes (eg, deaths, 
withdrawn consent) were excluded from the analysis. 
Five (3%) of 150 genotype 1a patients versus two (2%) of 
126 genotype 1b patients relapsed (p=0·46, two-sided 
Fisher’s exact test).
Among the 35 patients with genotype 4 HCV who were 
assessed for effi  cacy, SVR12 was achieved in 14 (78%, 
90% CI 56–92) of 18 patients receiving 12 weeks of 
Figure 1: Trial profi le
CTP=Child-Turcotte-Pugh. FCH=fi brosing cholestatic hepatitis. LDV=ledipasvir. 
RBV=ribavirin. SOF=sofosbuvir. *Patients excluded from the full analysis set used 
to analyse effi  cacy data: seven patients who received liver transplants before 
post-treatment week 12; and three patients who did not meet criteria for one of 
seven treatment groups after reanalysis (patients had not received a liver 
transplant nor were their screened CTP scores greater than or equal to 7).
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Cohort A: before transplantation Cohort B: after transplantation
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treatment and 16 (94%, 75–100) of 17 patients receiving 
24 weeks of treatment. Of the fi ve patients who did not 
achieve SVR12, three—all receiving 12 weeks of 
treatment—had virological relapse, and two died (one 
post-transplantation CTP-A on 12 weeks of treatment, 
and one untransplanted CTP-C on 24 weeks of 
treatment). All three patients who had virological relapse 
were patients with decompensated disease (one CTP-B 
and one CTP-C who had not received a previous liver 
transplant, one CTP-C who had received a liver 
transplant), who were treated for 12 weeks, and had a 
baseline NS5A resistance-associated variant. No patient 
with genotype 4 HCV who received 24 weeks of treatment 
had virological relapse. Two patients with genotype 4 
HCV were not included in the SVR12 analysis: one 
cohort A patient was found to have a CTP score of 5 upon 
recalculation of screening score (required to be ≥7 to 
enrol) and therefore did not meet the eligibility criteria 
for study and one received a liver transplant before post-
treatment week 12. This patient had HCV RNA less than 
LLOQ at the time of transplantation and continued to 
have HCV RNA less than LLOQ 12 weeks after 
transplantation.
During the study, ten patients (nine in cohort A and 
one in cohort B) underwent liver transplantation: four 
during the treatment phase, one after post-treatment 
Cohort A: before transplantation Cohort B: after transplantation
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Data are n (%), n/N (%), median (IQR), or mean (SD), unless otherwise stated. Some patient Child-Turcotte-Pugh (CTP) classes changed between enrolment and baseline visits. Glomerular fi ltration rate 
estimated (eGFR) using the Cockcroft-Gault Equation using lesser of actual and ideal bodyweight. FCH=fi brosing cholestatic hepatitis. HCV=hepatitis C virus. MELD=Model for End-stage Liver Disease. 
PI=protease inhibitor. PEG=peginterferon-alpha. *Other previous regimens include interferon monotherapy (n=6), interferon plus ribavirin (n=6), peginterferon monotherapy (n=6), sofosbuvir plus ribavirin 
(n=3), ribavirin monotherapy (n=3), and unknown (n=1). 
Table 1: Baseline demographic characteristics
Cohort A: before transplantation Cohort B: after transplantation








































































Relapse 3 1 1 1 1 0 0 0 0 0 0 0 0 0
Death 0 0 2 3 2 0 0 1 1 0 1 1 0 0




































Relapse 1 0 1 0 0 0 0 0 0 0 1 ·· ·· ··
Death 0 0 0 1 0 0 1 0 0 0 0 ·· ·· ··
Other 0 0 0 0 0 0 0 0 0 0 0 ·· ·· ··
SVR12 data are n/N (%, 90% CI). Patients who underwent liver transplantation (with HCV RNA <LLOQ at last measurement before transplant) before the post-treatment week 12 visit window are excluded from 
analysis. CTP=Child-Turcotte-Pugh. FCH=fi brosing cholestatic hepatitis. HCV=hepatitis C virus. LLOQ=lower limit of quantitation (15 IU/mL). SVR12=the proportion of patients achieving a sustained virological 
response 12 weeks after the end of therapy, defi ned as serum HCV RNA below the lower limit of quantifi cation. 
Table 2: Post-treatment outcomes
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week 2, two after post-treatment week 8, and three after 
post-treatment week 12. Six patients had CTP-C disease, 
and four had CTP-B disease. All received at least 11 weeks 
of study treatment before undergoing transplantation. 
HCV RNA was undetectable in all ten patients at the 
time of transplantation, and none developed recurrent 
HCV infection. The patient in cohort B underwent re-
transplantation after achieving SVR12. Of the ten 
patients, all achieved pTVR12.
NS5A pretreatment resistance analysis was done for 
308 patients: 276 with genotype 1 infection and 32 with 
genotype 4 infection. NS5B pretreatment resistance 
analysis was done for 305 patients: 275 with genotype 1 
and 30 with genotype 4 infection. Using a 1% deep 
sequencing cutoff , 59 (21%) of 276 patients with 
genotype 1 HCV infection had baseline NS5A resistance-
associated variants that confer reduced susceptibility to 
ledipasvir. Of these 59 patients, only two (3%) relapsed 
after 12 weeks of treatment. Five (2%) of 217 patients 
without baseline NS5A resistance-associated variants 
relapsed, three after 12 weeks of treatment and two after 
24 weeks of treatment. None of the 32 patients with 
NS5A resistance-associated variants who received 
ledipasvir–sofosbuvir plus ribavirin for 24 weeks 
relapsed. Of the 32 patients with genotype 4 HCV 
infection, 24 (75%) had NS5A resistance-associated 
variants. Three of them had virological relapse. Of the 
eight genotype 4 patients without baseline NS5A 
mutations, none had virological relapse.
Overall, ten patients had virological relapse: seven with 
genotype 1 infection (fi ve with genotype 1a and two with 
genotype 1b) and three with genotype 4 infection. Nine of 
the ten patients who relapsed had decompensated 
cirrhosis. Two (29%) of seven patients with genotype 1 
HCV infection who relapsed had NS5A resistance-
associated variants at pretreatment (positions Q30, L31, 
and Y93). At virological failure, all patients had NS5A 
variants: K24R, M28T, Q30H/K/R, L31M/V, and Y93H/C. 
The three patients with genotype 4 HCV who relapsed had 
L30H/R, M31V, P58L, and Y93C at the time of relapse.
At the time of relapse, the nucleotide inhibitor 
resistance-associated variant S282T was not recorded in 
any of the patients. Two patients with genotype 1a and 
genotype 4d infection had the variant E237G at the time 
of relapse. The clinical signifi cance of E237G is currently 
unknown.
We assessed the relation between achieving SVR12 and 
changes in MELD and CTP scores (fi gures 2 and 3). 
Improvements in MELD scores occurred in 58 (72%) of 
81 non-transplanted patients who achieved SVR12 and 
had measurements for MELD recorded for both baseline 
and week 12 of follow-up (fi gure 2A). A MELD score of at 
least 15 is generally the threshold at which liver 
transplantation is recommended.12 Although change in 
transplant eligibility was not specifi cally captured in the 
study, among non-transplanted patients whose MELD 
score was at least 15 at baseline, 20 (80%) of 25 patients 
had MELD scores less than 15 at post-treatment week 12. 
Conversely, among non-transplanted patients whose 
MELD score was less than 15 at baseline, two (4%) of 56 
had a MELD score of at least 15 at post-treatment week 12. 
For this same group of patients, 14 (28%) of 50 improved 
from CTP-B at baseline to CTP-A at post-treatment 
week 12 and 21 (68%) of 31 improved from CTP-C at 
baseline to CTP-B cirrhosis at post-treatment week 12.
Most patients with either CTP-B or CTP-C disease who 
had undergone liver transplantation also had improved 
MELD scores (25/43, 58%). Among post-transplanted 
patients with decompensated cirrhosis whose MELD 
Figure 2: Individual Model for End-Stage Liver Disease (MELD) score changes from baseline to post-treatment 
week 12 in pre-transplantation and post-transplantation decompensated (Child-Turcotte-Pugh [CTP]-B or 
CTP-C) patients who achieved sustained virological response 12 weeks after treatment
Change from baseline in MELD scores in non-transplanted patients in groups 1 and 2 (A) and post-transplantation 
patients in groups 5 and 6 (B). MELD score=10 × ([0·957 × loge(Scr)] + [0·378 × loge(Tbil)] + [1·12 × loge(INR)] + 0·643), 
where Scr is serum creatinine (mg/dL), Tbil is total bilirubin (mg/dL), and INR is international normalisation ratio. 
Laboratory values less than 1·0 were set to 1 in formula; for patients receiving dialysis at least two times in the last 
week, serum creatinine was set to 4·0 mg/dL for the calculation. Missing follow-up at post-treatment week 12: 























































CTP-C 12 weeks (n=16) CTP-C 24 weeks (n=19)
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score was at least 15 at baseline, fi ve (63%) of eight had 
MELD scores less than 15 at post-treatment week 12. 
Conversely, among those whose MELD score was less 
than 15 at baseline, three (9%) of 35 had a MELD score of 
at least 15 at post-treatment week 12. For this same group 
of patients, 17 (52%) of 33 improved from CTP-B at 
baseline to CTP-A at post-treatment week 12, and three 
(60%) of fi ve improved from CTP-C to CTP-B cirrhosis.
Rates of adverse events were consistent with the study 
population having advanced liver disease (table 3). 
However, 316 (95%) of 333 patients completed study 
treatment, and only seven patients (2%) discontinued 
ledipasvir–sofosbuvir dosing prematurely because of an 
adverse event (table 3). Of the adverse events leading to 
discontinuation from ledipasvir–sofosbuvir, only one 
event, hepatocellular carcinoma, led to discontinuation 
in more than one patient (n=2). 72 patients (22%) had 
serious adverse events (appendix). Nine serious adverse 
events were considered treatment-related: anaemia 
(n=5), diarrhoea (n=1), fall (n=1), hyperbilirubinaemia 
(n=1), and vomiting (n=1). The fall was not considered 
related to ledipasvir–sofosbuvir by the investigator, but 
rather due to ribavirin-mediated anaemia.
Among the 226 post-transplantation patients in 
cohort B included in the effi  cacy analysis, the most com-
monly used immunosuppressants were tacrolimus or 
tacro limus monohydrate in 144 patients (64%), myco pheno-
late mofetil, mycophenolate sodium, or myco phenolic acid 
in 100 patients (44%), and cyclosporine in 63 patients (28%). 
Less commonly used immuno suppressants were sirolimus 
(11 patients [5%]) and everolimus (nine patients [4%]). No 
patients had changes in immunosuppressant medications 
that were attributed to drug interaction with study treatment. 
Ten patients required an increase in immunosuppressant 
dosing (tacrolimus for all ten), possibly because of altered 
hepatic function after viral clearance.
17 patients died during the study (appendix). Of these, 
ten patients died within 30 days of treatment; seven 
patients died more than 30 days after the end of 
treatment. 11 (65%) of the 17 deaths occurred in patients 
with decompensated CTP-C cirrhosis. Additionally, two 
patients with decompensated CTP-B cirrhosis died; one 
because of a decompensation event and the other because 
of small bowel pneumatosis. Two patients with stage 
F0–F3 fi brosis died from bronchial carcinoma and graft 
failure secondary to rejection, respectively. Two patients 
with compensated (CTP-A) cirrhosis died, one from 
myocardial infarction and the other from hepatic 
decompensation.
Across all groups, the most common grade 3 or 4 
laboratory abnormalities were decreases in haemoglobin 
and lymphocytes and increases in total bilirubin and 
glucose. Median creatinine concentrations in all groups 
remained stable while on treatment. Decreases in 
haemoglobin and lymphocytes are known complications 
of ribavirin therapy, which in this study probably 
exacerbated pre-existing anaemia and lymphopenia. 
Increases in total bilirubin also occurred, almost 
exclusively due to an increase in indirect bilirubin, which 
is another known complication of ribavirin therapy. 
Glucose abnormalities were only recorded in patients 
with known pre-existing issues with glycaemic control.
The average daily dose of ribavirin in patients with 
decompensated cirrhosis (non-transplanted or post-
transplantation) was about 600 mg. The average daily 
dose of ribavirin in patients with no cirrhosis or 
compensated cirrhosis was about 800 mg. Ribavirin 
dosing was reduced in 134 patients (40%), interrupted in 
26 patients (8%), and discontinued in 40 patients (12%). 
Dose discontinuation was not associated with virological 
relapse.
Discussion
In this open-label trial, the all-oral combination of 
ledipasvir–sofosbuvir plus ribavirin for 12 or 24 weeks 
Figure 3: Individual changes in Child-Turcotte-Pugh (CTP) scores from baseline to post-treatment week 12 in 
pre-transplantation and post-transplantation decompensated (CTP-B or CTP-C) patients who achieved 
sustained virological response 12 weeks after treatment
Change from baseline in CTP scores in non-transplanted patients in groups 1 and 2 (A) and post-transplantation 
patients in groups 5 and 6 (B). CTP score was calculated as the sum of the fi ve scores assigned for total bilirubin, serum 
albumin, international normalised ratio, ascites, and hepatic encephalopathy. Missing follow-up at post-treatment 







































CTP-B 12 weeks (n=26) CTP-B 24 weeks (n=24) CTP-C 12 weeks (n=12) CTP-C 24 weeks (n=19)
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Cohort A: before transplantation Cohort B: after transplantation




































































































Adverse events leading to discontinuation
Ledipasvir–sofosbuvir
Oedema 0 0 0 1
(4%)
0 0 0 0 0 0 0 0 0 0
Dehydration 0 0 0 0 0 0 0 0 0 0 0 1
(20%)
0 0
Diabetes type 2 0 0 0 0 0 0 0 1
(3%)







0 0 0 0 0 0 0 0 0 0
Hepatic failure 0 0 0 0 1
(2%)
0 0 0 0 0 0 0 0 0
Hyperbilirubinaemia 0 1
(4%)





















Chills 0 0 0 0 0 0 0 1
(3%)
0 0 0 0 0 0
Cough 0 0 0 0 0 0 0 1
(3%)
0 0 0 0 0 0
Hyperbilirubinaemia 0 1
(4%)
0 0 0 0 0 0 0 0 0 0 0 0
Diarrhoea 0 0 0 0 0 0 0 1
(3%)
0 0 0 0 0 0
Disturbance in 
attention
0 0 0 0 0 0 0 1
(3%)
0 0 0 0 0 0
Dysarthria 0 0 0 0 0 0 0 1
(3%)
0 0 0 0 0 0




0 0 0 0 0 0
Eczema 0 0 0 0 0 1
(2%)
0 0 0 0 0 0 0 0
Oedema 0 0 0 1
(4%)





0 0 0 0 0 0 0 0 0 0 0
Gastric varices 
haemorrhage
0 0 0 0 0 1
(2%)





0 0 0 0 0 0 0 0 0 0 0
Headache 0 0 0 0 1
(2%)







0 0 0 0 0 0 0 0 0 0
Hepatorenal 
syndrome
0 0 0 1(4%) 0 0 0 0 0 0 0 0 0 0
Dehydration 0 0 0 0 0 0 0 0 0 0 0 1
(20%)
0 0
(Table 3 continues on next page)
Articles
www.thelancet.com/infection   Vol 16   June 2016 695
resulted in high rates of SVR in patients with HCV 
genotype 1 or 4 and advanced liver disease both before 
and after liver transplantation, including those with 
fi brosing cholestatic hepatitis. Patients who underwent 
transplantation had received at least 11 weeks of antiviral 
treatment before transplantation, and they maintained 
HCV RNA less than the LLOQ after transplantation.
Rates of relapse were low and were most frequently 
seen in non-transplanted patients with decompensated 
cirrhosis. Among post-transplantation patients with HCV 
genotype 1, only one (<1%) of 193 relapsed. Additionally, 
treatment duration did not appear to have an eff ect on 
virological response rates for patients with genotype 1 
infection, a result that is consistent with the results from 
SOLAR-1, which also suggested that treatment duration 
was not associated with any diff erence in virological 
response rates in patients with genotype 1 HCV.
Overall, similar SVR rates were recorded in patients 
with and without baseline NS5A resistance-associated 
variants whether using a 1% cutoff  or 15% cutoff  for both 
genotype 1 and genotype 4. Future studies should 
examine if certain patients with specifi c NS5A resistance-
associated variants or certain combinations of resistance-
associated variants might need 24 weeks of treatment.
Of note, in the European Union, ledipasvir–sofosbuvir 
plus ribavirin for 24 weeks is indicated for genotype 1 
patients with decompensated cirrhosis or those who have 
undergone liver transplantation or both. The results of 
both the SOLAR-1 and SOLAR-2 trials suggest that a 
shortened course of 12 weeks of ledipasvir–sofosbuvir 
plus ribavirin is probably suffi  cient treatment for nearly 
all patients with genotype 1 HCV who have decompensated 
cirrhosis or with genotype 1 HCV recurrence post-liver 
transplantation.
Consistent with these conclusions, the 2015 HCV 
treatment guidelines from the European Association for 
the Study of the Liver (EASL) recommend 12 weeks of 
ledipasvir–sofosbuvir plus ribavirin as a fi rst-line option 
for HCV genotype 1 patients either with decompensated 
cirrhosis (CTP-B or CTP-C) or with compensated or 
decompensated cirrhosis after liver transplantation.13 The 
same recommendations have been made by the 
American Association for the Study of Liver Diseases 
(AASLD) and the Infectious Diseases Society of America 
(IDSA).14 Recommendations for other regimens for 
patients with advanced liver disease vary by region. EASL 
guidelines recommend sofosbuvir plus daclatasvir with 
weight-based ribavirin for 12 weeks as another fi rst-line 
option in patients with HCV genotype 1 either with 
decompensated cirrhosis (CTP-B or CTP-C) or with 
compensated or decompensated cirrhosis after liver 
transplantation.13
AASLD/IDSA guidelines recommend ombitasvir–
paritaprevir–ritonavir and dasabuvir plus ribavirin for 
24 weeks in liver transplant recipients with genotype 1 
HCV, but this regimen is restricted to those without 
fi brosis or with mild fi brosis.14
By contrast with SOLAR-1, which enrolled only fi ve 
patients with genotype 4 HCV, this study enrolled 
37 patients with genotype 4 infection. Of these, two were 
not assessed for effi  cacy—one was enrolled in error and 
one received a liver transplant before SVR12 with HCV 
RNA less than the LLOQ at transplantation—and two 
additional patients were not assessed for relapse because 
they died before reaching post-treatment week 12. Of the 
remaining 33, three patients (9%) relapsed, all of whom 
had decompensated cirrhosis and received 12 weeks of 
treatment. Thus, although it is reasonable to conclude 
Cohort A: before transplantation Cohort B: after transplantation





























(Continued from previous page)
Lethargy 0 0 0 0 0 0 0 1
(3%)
0 0 0 0 0 0
Pleuritic pain 0 0 0 0 0 0 0 1
(3%)
0 0 0 0 0 0
Pyrexia 0 0 0 0 0 0 0 1
(3%)
0 0 0 0 0 0
Rash 0 0 0 0 0 0 0 0 1
(5%)
0 0 0 0 0
Renal impairment 0 0 0 0 0 0 0 0 1
(5%)





0 0 0 0 0 0 0 0 0 0 0
Vision blurred 0 0 0 0 0 0 0 1
(3%)
0 0 0 0 0 0
Data are n (%). CTP=Child-Turcotte-Pugh. FCH=fi brosing cholestatic hepatitis. *Deaths occurring from the beginning of treatment until 30 days after the end of treatment.
Table 3: Adverse events and adverse events leading to study drug discontinuation
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that post-transplantation patients with HCV recurrence 
who have compensated disease can receive 12 weeks of 
treatment, it is challenging to make defi nitive conclusions 
about the optimum duration of therapy for genotype 4 
patients with decompensated disease based on this still 
limited number of patients.
Whereas SVR12 rates describe the virological response, 
changes in MELD and CTP scores describe the clinical 
response seen in patients. Such changes between start of 
treatment until 12 weeks after end of treatment were 
assessed for all decompensated patients (before and 
after transplantation) who achieved SVR12. Most 
patients with decompensated cirrhosis had improve-
ments in MELD and CTP scores with viral eradication. 
Similar improvements in patients with hepatic 
decompensation were reported in the SOLAR-1 study of 
HCV antiviral therapy,11 in real-world patients with 
advanced liver disease due to HCV who were treated 
with regimens including directly acting antivirals,15 and 
in studies of hepatitis B antiviral therapy in patients with 
hepatitis B-related advanced liver disease,16,17 suggesting 
virological suppression or eradication might improve 
hepatic function. Thus, successful viral eradication 
might aff ect both morbidity and mortality for most 
patients with decompensated disease. A long-term, 
5-year study is underway to quantify this and to assess 
whether there is a point of no return (ie, a degree of 
hepatic impairment for which it is futile to treat). In this 
study, and in SOLAR-1, patients with CTP scores greater 
than 12 were excluded due to their high near-term 
mortality.
For the small subgroup of decompensated patients 
who are or might be eligible for liver transplantation, 
however, improving their MELD score and eradicating 
their HCV infection before transplantation might have a 
paradoxical consequence. Such patients might lose their 
eligibility or priority for transplantation as their MELD 
score decreases; this possibility must be weighed against 
the time available for completing treatment before 
transplantation, the possibility of death while waiting for 
a transplant (or death during transplantation), as well as 
public health considerations given the general shortage 
of transplantable liver organs. Future studies will have to 
show whether HCV eradication is able to improve liver 
function to such an extent that patients can be removed 
from the waiting list.
All patients with fi brosing cholestatic hepatitis (5/5), a 
population that until recently had few treatment options 
and high mortality, achieved SVR12 after treatment with 
ledipasvir–sofosbuvir plus ribavirin for 12 or 24 weeks. 
These results are comparable to those seen when patients 
with fi brosing cholestatic hepatitis were treated with 
sofosbuvir plus daclatasvir (100% SVR12, 15/15) or 
sofosbuvir plus ribavirin (88% SVR12, 7/8).18
Despite the promising results, this study has several 
limitations. The small sample sizes do not allow 
defi nitive conclusions to be made about the eff ect of 
treatment in subgroups. The need for ribavirin, especially 
among patients without decompensated disease, was not 
assessed and needs to be defi ned in future studies. All 
patients in this study had MELD scores of 25 or below at 
baseline—in some European countries patients without 
hepato cellular carcinoma are eligible for liver trans-
plantation only if they have MELD scores higher than 30. 
Another limitation was the exclusion of patients with an 
estimated glomerular fi ltration rate less than 30 mL/min.
In conclusion, ledipasvir–sofosbuvir plus ribavirin is 
an eff ective treatment for patients with HCV genotype 1 
or 4 and advanced liver disease, including those with 
decompensated liver function, before and after liver 
transplantation. 12 weeks of treatment should become 
the standard of care for this group of patients. This all-
oral regimen provides a valuable treatment option for 
patients who most need one.
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